234 related articles for article (PubMed ID: 31755809)
1. Comparison of Efficacy of Intravitreal Ranibizumab and Aflibercept in Eyes with Myopic Choroidal Neovascularization: 24-Month Follow-Up.
Korol A; Kustryn T; Zadorozhnyy O; Pasyechnikova N; Kozak I
J Ocul Pharmacol Ther; 2020 Mar; 36(2):122-125. PubMed ID: 31755809
[No Abstract] [Full Text] [Related]
2. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
[TBL] [Abstract][Full Text] [Related]
3. Comparison of structural and functional outcome of aflibercept versus ranibizumab in patients with myopic choroidal neovascularization.
Howaidy A; Eldaly ZH
Eur J Ophthalmol; 2021 Jan; 31(1):211-217. PubMed ID: 31690105
[TBL] [Abstract][Full Text] [Related]
4. Differences between pathologic and non-pathologic high myopia in 4-year outcomes of anti-VEGF therapy for macular neovascularization.
Honda Y; Miyata M; Miyake M; Hata M; Numa S; Mori Y; Ooto S; Tamura H; Ueda-Arakawa N; Muraoka Y; Takahashi A; Sado K; Kido A; Tsujikawa A
Sci Rep; 2024 Jun; 14(1):13399. PubMed ID: 38862630
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization.
Wang JK; Huang TL; Chang PY; Chen YT; Chang CW; Chen FT; Hsu YR; Chen YJ
Sci Rep; 2018 Sep; 8(1):14389. PubMed ID: 30258077
[TBL] [Abstract][Full Text] [Related]
6. Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy.
Ito A; Maruyama-Inoue M; Kitajima Y; Sato S; Inoue T; Yamane S; Kadonosono K
PLoS One; 2020; 15(6):e0235213. PubMed ID: 32579608
[TBL] [Abstract][Full Text] [Related]
7. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept.
Kaya F
J Fr Ophtalmol; 2017 Dec; 40(10):832-838. PubMed ID: 29113742
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.
Inoue M; Yamane S; Sato S; Sakamaki K; Arakawa A; Kadonosono K
Am J Ophthalmol; 2016 Sep; 169():95-103. PubMed ID: 27320059
[TBL] [Abstract][Full Text] [Related]
9. Aflibercept as primary treatment for myopic choroidal neovascularisation: a retrospective study.
Bruè C; Pazzaglia A; Mariotti C; Reibaldi M; Giovannini A
Eye (Lond); 2016 Jan; 30(1):139-45. PubMed ID: 26514244
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of 12 Months Outcome of As-needed Intravitreal Aflibercept or Ranibizumab for the Treatment of Naïve Patients with Age-related Macular Degeneration].
Umeda N; Hokao K; Tsukahara T; Okamura K; Uchio E
Nippon Ganka Gakkai Zasshi; 2015 Dec; 119(12):839-45. PubMed ID: 26817131
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study.
Ikuno Y; Ohno-Matsui K; Wong TY; Korobelnik JF; Vitti R; Li T; Stemper B; Asmus F; Zeitz O; Ishibashi T;
Ophthalmology; 2015 Jun; 122(6):1220-7. PubMed ID: 25745875
[TBL] [Abstract][Full Text] [Related]
12. Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.
Cohen SY; Nghiem-Buffet S; Grenet T; Dubois L; Ayrault S; Fajnkuchen F; Delahaye-Mazza C; Quentel G; Tadayoni R
Jpn J Ophthalmol; 2015 Jan; 59(1):36-42. PubMed ID: 25416566
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
Cho HJ; Kim KM; Kim HS; Han JI; Kim CG; Lee TG; Kim JW
Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
[TBL] [Abstract][Full Text] [Related]
14. The Evaluation of a Two-Year Outcome of Intravitreal Conbercept versus Ranibizumab for Pathological Myopic Choroidal Neovascularization.
Chen C; Yan M; Huang Z; Song YP
Curr Eye Res; 2020 Nov; 45(11):1415-1421. PubMed ID: 32191134
[No Abstract] [Full Text] [Related]
15. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F
Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
[TBL] [Abstract][Full Text] [Related]
16. Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.
Karasu B; Gunay BO
Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):99-106. PubMed ID: 31768680
[TBL] [Abstract][Full Text] [Related]
17. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
[TBL] [Abstract][Full Text] [Related]
18. FIVE-YEAR OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH PATHOLOGIC MYOPIA.
Onishi Y; Yokoi T; Kasahara K; Yoshida T; Nagaoka N; Shinohara K; Kaneko Y; Suga M; Uramoto K; Ohno-Tanaka A; Ohno-Matsui K
Retina; 2019 Jul; 39(7):1289-1298. PubMed ID: 29746414
[TBL] [Abstract][Full Text] [Related]
19. AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: As Needed Versus Fixed Interval Dosing.
Inoue M; Yamane S; Taoka R; Arakawa A; Kadonosono K
Retina; 2016 Aug; 36(8):1527-34. PubMed ID: 26710307
[TBL] [Abstract][Full Text] [Related]
20. Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-month results from a randomized controlled study.
Li S; Ding X; Sun L; Zhao X; Zhang A; Lyu C; Liu B; Zhang J; Jin C; Lu L
Clin Exp Ophthalmol; 2019 Mar; 47(2):250-258. PubMed ID: 30345611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
